- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02245477
Maternal Serum Vascular Endothelial Growth Factor in Pregnant Women With Foetal Growth Restriction (VEGF in FGR)
January 30, 2021 updated by: Nesreen Abdel Fattah Abdullah Shehata, Beni-Suef University
Evaluation of Maternal Serum VEGF in Pregnant Women With Foetal Growth Restriction
In this study we explore To explore the role of maternal serum vascular endothelial growth factor (VEGF) in pregnancies complicated by foetal growth restriction.
Study Overview
Status
Unknown
Conditions
Intervention / Treatment
Detailed Description
Small-for-gestational age (SGA) is defined as an estimated foetal weight (EFW) or abdominal circumference (AC) less than the 10th centileand severe SGA as an EFW or AC less than the 3rd centile.
Foetal Growth Restriction refers to failure of the foetus to achieve its predetermined growth potential for various reasons.Foetus with foetal growth restriction (FGR) greatly contributes to perinatal mortality and short- and long-term morbidity.
There is a 3-10 fold increase in perinatal mortality in pregnancies complicated by this FGR .The incidence of FGR in newborns ranges between 3 and 7% of the total population .FGR is thought to stem from placental hypoxia-induced vasoconstriction of the fetoplacental vessels, leading to placental hypoperfusion and thus fetal undernutrition.
However, the effects of hypoxia on the fetoplacental vessels have been surprisingly little studied.Vascular endothelial growth factor (VEGF) is one of the factors that take part in placental angiogenesis.
It is highly expressed during embryonic and foetal development..Angiogenesis involves the branching of new microvessles from pre-existing larger blood vessels.Angiogenesis plays a role in the development of the villous vasculature and the formation of terminal villi in human placenta.
IUGR occurs as a result of the failure of elongation, branching and dilatation of the capillary loops and of terminal villous formation.
Study Type
Observational
Enrollment (Anticipated)
100
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
-
Cairo, Egypt
- Recruiting
- Nesreen Abdel Fattah Abdullah Shehata
-
Contact:
- Nesreen A Shehata, MD
- Phone Number: 00201024150605
- Email: nesoomar@yahoo.com
-
Principal Investigator:
- Nesreen A Shehata, MD
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
20 years to 40 years (Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
Female
Sampling Method
Non-Probability Sample
Study Population
Patients with gestational age 28-36 weeks were included in our study.
Patients with SGA were defined by obstetric ultrasound as estimated fetal weight was below the10thcentile.Twice weekly CTGs and Umbilical artery (UA) Doppler were done.
Women with abnormal CTGs or UA Doppler were excluded from the study.
A follow up scan was done 2 weeks later and FGR will be diagnosed if fetal weight had faltered.
Description
Inclusion Criteria:
- Age 20-40 years
- Gestational age 28-36 weeks
- Fetal growth restriction
- Patient consents to the procedure.
- BMI 20-30
Exclusion Criteria:
- Preeclampsia
- Diabetes Mellitus
- Fetal congenital anomalies
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
Cohorts and Interventions
Group / Cohort |
Intervention / Treatment |
---|---|
Obstetric Ultrasoud
Transabdominal ultrasound was performed to confirm foetal number, viability, gestational age, exclusion of congenital anomalies, and assessment of amniotic fluid index and localization of the placenta.
|
Transabdominal ultrasound was performed to confirm foetal number, viability, gestational age, exclusion of congenital anomalies, and assessment of amniotic fluid index and localization of the placenta.
|
Serum Vascular Endothelial Growth Factor
Serum VEGF concentration will be determined by Enzyme Linked immunosorbant assay using Quantitative Human VEGF Immunoassay kit (cat.
No. DVEOO) manufactured by R & D Systems, Inc , (Minneapolis, MN, USA).
|
Maternal blood samples (10 cc) were taken from an antecubital vein.
Plastic clean sterile tubes were used for collection of blood.
Two cc of the blood sample were put in other clean sterile tubes containing ethylene diamine tetra-acetic acid (EDTA) to be used in measuring maternal hemoglobin concentrations and evaluating the complete blood count.
The rest of maternal blood samples were centrifuged within 3 hours and sera collected equally in 2 suitable containers and stored at -80 degrees until assayed (first container for routine laboratory investigations and the second for VEGF assay).VEGF sample was allowed to clot for 30 minutes before centrifugation for 15 minutes.
Serum is removed and assay immediately or sample was stored at -80 degrees
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Obstetric ultrasound
Time Frame: from 28 weeks gestation to 36 weeks gestation
|
Patients with gestational age 28-36 weeks were included in our study.
Patients with SGA were defined by obstetric ultrasound as estimated fetal weight was below the10thcentile.
Twice weekly CTGs and Umbilical artery (UA) Doppler were done.
Women with abnormal CTGs or UA Doppler were excluded from the study.
A follow up scan was done 2 weeks later and FGR will be diagnosed if fetal weight had altered.
|
from 28 weeks gestation to 36 weeks gestation
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Serum Vascular Endothelial growth factor
Time Frame: 3 months until delivery
|
Maternal blood samples (10 cc) were taken from an antecubital vein.
Plastic clean sterile tubes were used for collection of blood.
Two cc of the blood sample were put in other clean sterile tubes containing ethylene diamine tetra-acetic acid (EDTA) to be used in measuring maternal hemoglobin concentrations and evaluating the complete blood count.
The rest of maternal blood samples were centrifuged within 3 hours and sera collected equally in 2 suitable containers and stored at -80 degrees until assayed (first container for routine laboratory investigations and the second for VEGF assay).VEGF sample was allowed to clot for 30 minutes before centrifugation for 15 minutes.
Serum is removed and assay immediately or sample was stored at -80 degrees.Serum VEGF concentration was determined by Enzyme Linked immunosorbant assay using Quantitative Human VEGF Immunoassay kit (cat.
No. DVEOO) manufactured by R & D Systems, Inc , (Minneapolis, MN, USA).
|
3 months until delivery
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start
September 1, 2014
Primary Completion (Anticipated)
June 1, 2021
Study Completion (Anticipated)
June 1, 2021
Study Registration Dates
First Submitted
September 17, 2014
First Submitted That Met QC Criteria
September 17, 2014
First Posted (Estimate)
September 19, 2014
Study Record Updates
Last Update Posted (Actual)
February 2, 2021
Last Update Submitted That Met QC Criteria
January 30, 2021
Last Verified
January 1, 2021
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- Beni-Suef 5
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Foetal Growth Restriction
-
Novo Nordisk A/SCompletedFoetal Growth Problem | Small for Gestational AgeIsrael, Spain, Sweden, Finland, Germany, Portugal, Czech Republic, Poland
-
Novo Nordisk A/SCompletedFoetal Growth Problem | Small for Gestational AgeFrance
-
Novo Nordisk A/SCompletedFoetal Growth Problem | Small for Gestational AgeSpain
-
Novo Nordisk A/SCompletedFoetal Growth Problem | Small for Gestational AgeSpain
-
Novo Nordisk A/SCompletedFoetal Growth Problem | Small for Gestational AgeNetherlands
-
University College DublinRoyal College of Surgeons, Ireland; National Maternity Hospital, Ireland; Perinatal...CompletedPlacenta Diseases | Pre-Eclampsia | Fetal Growth Retardation | Eclampsia Preeclampsia | Foetal Growth RestrictionIreland
-
University of British ColumbiaTerminatedIntrauterine Growth Restriction (IUGR) | Fetal Growth Restriction (FGR)Canada
-
Johns Hopkins UniversityWithdrawnFetal Growth Retardation | Intrauterine Growth Restriction | Intrauterine Growth Retardation | Fetal Growth Restriction
-
Hospices Civils de LyonUnknown
-
Assiut UniversityCompleted
Clinical Trials on obstetric Ultrasound
-
Ain Shams UniversityCompletedBirth Weight | Fetal Body WeightEgypt
-
Assiut UniversityNot yet recruitingShoulder Dystocia | Macrosomia, Fetal | Large for Gestational Age
-
Bridge to Health Medical and DentalKigezi Healthcare FoundationCompletedMaternal Health | Antenatal Care
-
National Cheng Kung UniversityMinistry of Science and Technology, TaiwanRecruiting
-
Maastricht University Medical CenterSchool for Midwifery MaastrichtCompleted
-
University of Campania "Luigi Vanvitelli"Completed
-
Brno University HospitalMasaryk University; Institute of Biostatistics and Analyses, Masaryk University... and other collaboratorsNot yet recruitingObstetric Anesthesia CareCzechia
-
Cengiz Gokcek Women's and Children's HospitalRecruiting
-
Oslo University HospitalEnrolling by invitationUrinary Incontinence | Sexual Dysfunction | Anal Incontinence | Obstetric Anal Sphincter InjuryNorway